ResMed (NYSE:RMD) Given New $225.00 Price Target at Piper Sandler

ResMed (NYSE:RMD) had its target price dropped by stock analysts at Piper Sandler from $233.00 to $225.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has a “neutral” rating on the medical equipment provider’s stock. Piper Sandler’s target price indicates a potential upside of 7.51% from the company’s previous close.

Several other research analysts have also commented on RMD. Jefferies Financial Group lowered their price target on ResMed from $240.00 to $225.00 and set a “hold” rating for the company in a research report on Friday, July 10th. Royal Bank Of Canada cut ResMed from an “outperform” rating to a “sector perform” rating and set a $234.00 target price for the company. in a report on Thursday, July 16th. UBS Group reiterated a “buy” rating and set a $300.00 price target on shares of ResMed in a research note on Tuesday, July 21st. Morgan Stanley reissued an “equal weight” rating and issued a $230.00 price objective (down from $286.00) on shares of ResMed in a research note on Wednesday, June 17th. Finally, Mizuho cut their target price on shares of ResMed from $235.00 to $220.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th. Seven investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $239.33.

ResMed Trading Down 6.2%

Shares of RMD stock traded down $13.95 during trading hours on Friday, hitting $209.29. The company had a trading volume of 1,992,643 shares, compared to its average volume of 1,295,438. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.01 and a quick ratio of 2.33. The stock has a market capitalization of $30.36 billion, a PE ratio of 20.21, a price-to-earnings-growth ratio of 1.36 and a beta of 0.76. The company’s fifty day moving average is $200.06 and its 200 day moving average is $222.30. ResMed has a fifty-two week low of $180.26 and a fifty-two week high of $293.81.

ResMed (NYSE:RMD) last posted its earnings results on Thursday, August 6th. The medical equipment provider reported $2.95 earnings per share for the quarter, beating the consensus estimate of $2.89 by $0.06. The firm had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.46 billion. ResMed had a net margin of 27.44% and a return on equity of 25.35%. The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.55 EPS. Research analysts expect that ResMed will post 11.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Michael J. Farrell sold 4,991 shares of the business’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $218.55, for a total transaction of $1,090,783.05. Following the completion of the transaction, the chief executive officer owned 466,223 shares in the company, valued at approximately $101,893,036.65. The trade was a 1.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter C. Farrell sold 8,000 shares of the stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $225.00, for a total value of $1,800,000.00. Following the completion of the transaction, the director directly owned 52,773 shares in the company, valued at $11,873,925. This trade represents a 13.16% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 17,982 shares of company stock worth $3,858,837. Insiders own 0.65% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in RMD. BlackRock Inc. purchased a new position in ResMed in the second quarter valued at approximately $2,400,375,000. Bank of New York Mellon Corp purchased a new stake in shares of ResMed during the 2nd quarter worth approximately $818,030,000. Deutsche Bank AG acquired a new position in shares of ResMed in the 2nd quarter valued at $257,692,000. First Trust Advisors LP boosted its holdings in shares of ResMed by 240.9% in the 4th quarter. First Trust Advisors LP now owns 1,517,592 shares of the medical equipment provider’s stock valued at $365,542,000 after buying an additional 1,072,394 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of ResMed in the 4th quarter valued at $249,068,000. 54.98% of the stock is owned by institutional investors and hedge funds.

ResMed News Summary

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: ResMed reported fiscal fourth-quarter EPS of $2.95, above the approximately $2.89–$2.90 consensus and up from $2.55 a year earlier. Revenue rose 8.6% year over year to $1.46 billion, matching expectations and supporting the company’s ongoing growth story. ResMed Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: The company increased its dividend while reporting strong fourth-quarter and full-year fiscal 2026 results, which could enhance ResMed’s appeal to income-focused investors. ResMed Posts Strong Q4 Earnings and Lifts Dividend
• Neutral Sentiment: Despite the EPS beat, revenue was merely in line with forecasts. Analysts maintain an overall “Hold” view, reflecting mixed expectations for future growth amid tariff, inflation and healthcare-spending pressures. ResMed Receives Average Hold Rating
• Negative Sentiment: Wells Fargo lowered its price target from $225 to $215 and reiterated an “equal weight” rating, leaving limited implied upside based on the latest quoted price. The reduction reinforces concerns that the earnings results may already be reflected in the valuation. Benzinga Analyst Target Update
• Negative Sentiment: Director Peter Farrell sold 8,000 shares for approximately $1.8 million. Because the sale occurred under a pre-arranged Rule 10b5-1 plan, its negative signaling value is limited, but it may still contribute modest selling pressure. SEC Insider Trading Filing

About ResMed

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.